Celebrating Scientific Advancement Amarin applauds the groundbreaking work addressing sHTG and rare genetic disorders such as familial chylomicronemia syndrome (FCS). These advances help drive patient ...
VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant ...
Detailed price information for Amarin Corp ADR (AMRN-Q) from The Globe and Mail including charting and trades.
Completed concept studies for expansion of South Carolina and Nevada hubs, increasing total HyProMag USA magnet and alloy production from 1,552 metric tons NdFeB to 4,656 metric tons NdFeB per annum, ...
DPM Metals Inc. (TSX: DPM, ASX: DPM) (ARBN: 689370894) ("DPM" or "the Company") announced preliminary production results for the three and twelve months ended ...
Discover how absorption costing is used in GAAP for external reporting. Learn its components and why it's essential for ...
Karooooo is expected to report financial results for the Third Quarter 2026 ended November 30, 2025 on Tuesday, January 20, ...
Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced select preliminary unaudited 2025 financial ...
Tharisa, the mining, metals, and innovation company dual-listed on the Johannesburg and London stock exchanges, announces its production results for Q1 FY2026[1] and cash balance as at 31 December 202 ...
All amounts are in Canadian Dollars unless otherwise noted Base Case - US$3,100/oz Au and C$/US$ exchange rate of 1.35: After-Tax NPV : $652 million Payback Period: 2.7 years NPV to Capex: 1.4x ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback